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Letters to the Editorproduction. In fact, normoxemic
reperfusion of a distal ischemic organ
(eg, the intestine) has been shown to
cause myocardial injury that was
prevented with progressive oxygen
re-entry during reperfusion.4
Second, in the above studies, similarly
to the current one, with the exception
of MDA measurement, the favorable
effect of hypoxemic reperfusion was
not substantiated by direct indices of
oxidative stress alterations, such as
ROS measurement. ROS and cytokines
were recently assessed in a model of
hypoxemic resuscitation of hemorrhagic
shock in rabbits and found to be particu-
larly diminished compared with those
seen in the standard resuscitation mode
of clinical practice.5 The weakening
effect on cytokine production is an
additional important achievement of
hypoxemic resuscitation because these
mediators lead to post–ischemia–reper-
fusion inflammatory injury.
Third, the authors have repetitively
used erroneously the term ‘‘hypoxic
reoxygenation’’ instead of ‘‘hyper-
oxic reoxygenation’’ to describe
PaO2 values of 250 to 350 mm Hg,
which is usually applied in the clini-
cal setting. Furthermore, we consider
even more accurate the term ‘‘hyper-
oxemic’’ because it describes higher
arterial oxygen content largely and
easily modifiable by fraction of in-
spired oxygen changes; in contrast,
the term ‘‘hyperoxic’’ describes tis-
sue oxygen concentration dependent
on addition to hemodynamic parame-
ters. Correspondingly, the other treat-
ment branch is represented by gradual
reoxygenation by means of an initial
‘‘hypoxemic’’ instead of ‘‘hypoxic’’
period.
Our published data support the
findings of Abdel-Rahman and col-
leagues1 regarding the principal idea
of the strategy for the prevention of re-
perfusion injury,2-4 the restoration of
hemodynamic parameters,4,5 and the
attenuation of oxidative stress.2–5 Ad-
ditionally, these data provide a further
insight into the potentially protective
role of this strategy through the atten-1358 The Journal of Thoracic anduation of the inflammatory response
during reperfusion.5
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STATINS: ANOTHER
PLEIOTROPIC BENEFIT?
To the Editor:
We read with interest the recent trial
by Hillis and associates,1 demonstrat-
ing that hyperuricemia was associated
with poorer survival after coronary ar-
tery bypass grafting (CABG), indepen-
dently of other risk factors, including
the European System for Cardiac Op-
erative Risk Evaluation (Euro-
SCORE). Also, this increased risk
was particularly evident among pa-
tients with levels in the upper quartile.
It has been showed that treatment
with statins2 can reduce serum uricCardiovascular Surgery c May 2010acid (SUA) levels; thus they would
have an additional beneficial effect
apart from that derived for lowering
low-density lipoprotein cholesterol
(LDL-c) levels. However, little infor-
mation is available about the effects
of high doses of statins on the SUA
levels. The present study focuses on
the possible effect of using a high
dose of atorvastatin on SUA levels.
We therefore hypothesized that the
use of the highest dose of atorvastatin
(80 mg/day) in high-risk patients un-
der treatment with atorvastatin 40
mg/day would reduce SUA levels.
We studied 29 ‘‘high-risk’’ patients
(inclusion criteria: severe triple vessel
disease but rejected for bypass for ex-
tensive coronary disease, severe effort
angina after coronary artery bypass,
and premature coronary disease with
 3 risk factors) with an abnormal
lipid profile despite atorvastatin 40
mg/day at baseline and at 3 months af-
ter increasing the dose to 80 mg/day.
Baseline results in patients were com-
pared with those of 39 healthy con-
trols. The lipid profile, C-reactive
protein levels (CRP), SUA levels of
patients and controls, and the changes
after increasing doses of atorvastatin
are shown in Table 1, A and B. At base-
line, patients had higher levels of SUA
(P ¼ .036) compared with controls.
Follow-up was completed in a total
of 26 patients (2 patients withdrew
voluntarily from the study and 1 pa-
tient had no samples at 3 months). Af-
ter the dose of atorvastatin had been
increased, a significant decrease in
CRP (P ¼ .004) and SUA (P ¼ .018)
levels were detected among treated pa-
tients. Also, these reductions did not
show correlation with the changes of
lipid profile (cholesterol, triglycerides,
LDL-c, and high-density lipoprotein
cholesterol). No adverse effects were
observed in any patients.
The present study shows that in-
creasing doses of atorvastatin at 80
mg reduces SUA levels compared
with the 40-mg dose in high-risk pa-
tients with ischemic heart disease. Pre-
vious studies have shown that
TABLE 1. A. Test values of patients and controls. B. Test values at baseline (atorvastatin 40 mg/day) and 3 months of study (atorvastatin
80 mg/day).
Part A Patients (n ¼ 29) Controls (n ¼ 39) P value Part B Baseline (n ¼ 26) Postintervention (n ¼ 26) P value
SUA (mg/dL) 6.0 (4.9–6.9) 5.2 (4.0–6.1) .036 6.0 (4.9–6.8) 5.8 (4.8–6.4) .018
Total cholesterol (mg/dL) 221 (228–252) 230 (204–249) .862 229 (201–258) 192 (173–217) .001
HDL-c (mg/dL) 42 (37–52) 50 (43–56) .011 42 (36–50) 42 (38–48) .517
LDL-c (mg/dL) 145 (130–174) 155 (130–177) .820 146 (131–175) 122 (95–138) .001
Triglycerides (mg/dL) 163 (97–252) 110 (77–146) .008 166 (87–250) 132 (103–194) .201
CRP (mg/dL) 0.30 (0.16–0.64) 0.15 (0.07–0.37) .019 0.32 (0.17–0.69) 0.14 (0.09–0.34) .004
n, Sample size; SUA, serum uric acid levels; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol, CRP, C-reactive protein.
Letters to the Editorpreoperative statin therapy can reduce
cardiac mortality after CABG by
means of mechanisms that are inde-
pendent of their cholesterol-lowering
properties.3 We suggest that one of
these mechanisms may be the hypour-
icemic effect of statins. The underly-
ing mechanisms of this effect of
statins are not clear-cut. It has been
speculated that statins increase renal
blood flow and, thus, increase renal ur-
ate excretion and lower serum creati-
nine levels.4 According to the results
shown by Hillis and associates1 and
given that measurement of SUA is
a routine procedure with repeatable re-
sults in clinical laboratories, we pro-
pose the clinical importance of
monitoring and intervention on the ba-
sis of increased SUA levels and re-em-
phasize the positive effect of using
high doses of statins.5
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OF ENDOVASCULAR
THERAPIES DURING TYPE A
ACUTE AORTIC DISSECTION
REPAIR
To the Editor:
We read with interest the article of
Sun and coworkers1 on the use of the
stented elephant trunk for type A acute
aortic dissection (TAAD). The aim of
this hybrid approach is to stabilize
the residual dissected aorta and thus
prevent late thoracoabdominal aneu-
rysm formation and the need for reop-
eration. Even though the idea is
extremely attractive, we are doubtful
that stenting the descending aorta is
really needed during TAAD repair. In-
deed, a literature review reveals that
expansion of the residual dissected
aorta after surgical repair is a slow
and linear process that makes distal re-
operations relatively uncommon. In an
article published on the same issue of
this Journal, Stevens and collegues,2of Thoracic and Cardiovascular Surgerreporting the 25-year experience of
the Massachusetts General Hospital
with 195 patients treated for TAAD,
concluded: ‘‘Aortic reoperations were
infrequent during follow-up.’’ In
another recent paper, Geirrson and
collegues3 reported that only 12 of
221 patients required late reoperation
for thoracoabdominal aneurysm.
Similarly, Dobrilovic and Elefter-
iades4 reported just 4 distal reoperation
in a series of 200 patients operated on
for TAAD.3 Taking these data into
consideration, we believe that adjunc-
tive descending endovascular stent
grafting during emergency surgical
repair might add supplementary risk
to an alredy complex procedure with
a high mortality rate, stabilizing some-
thing that has a low probability to
cause a surgical problem in the future.
In our opinion, a solution to im-
prove long-term results of TAAD is
represented by combining a radical
surgical resection with an extensive
arch debranching to create a safe and
long proximal landing zone for sub-
sequent endovascular procedures on
the descending aorta, if needed.
Our technique consists in replacing
the ascending aorta and the arch and re-
locating the origin of the supra-aortic
vessels very proximally just above the
sinotubular junction, using a specially
designed quadrifurcated vascular
prosthesis (The Plexus 4-Branch;
Vascutek Terumo Inc, Scotland, United
Kingdom). If the patient will be one of
the few who needs a second procedure
on the descending aorta, this preventive
debranching will allows a safe and
effective endovascular treatment in
both the short and the long term.y c Volume 139, Number 5 1359
